SCHEMBL8645965

SCHEMBL8645965

C#Cc1ccc([Si](c2ccccc2)(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 2/20 0.42
PTPN1 P18031 1/20 0.38
CYP2C9 P11712 3/20 0.37
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA4 P22748 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
KEAP1 Q14145 1/20 0.34
GABRA1 P14867 2/20 0.34
GABRG2 P18507 2/20 0.34
GABRB3 P28472 2/20 0.34
GABRA5 P31644 2/20 0.34
GABRA3 P34903 2/20 0.34
GABRA2 P47869 2/20 0.34
MPO P05164 1/20 0.33
EGLN2 Q96KS0 1/20 0.33
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5929955 1.00 HDAC8 (0.42) HDAC8PTPN1CYP2C9CA12CA1
SCHEMBL28574091 0.90 HDAC8 (0.50) HDAC8PTPN1CYP2C9CA12CA1
SCHEMBL12124388 0.80 APP (0.55) CYP2C9CA12CA1CA2CA9
SCHEMBL15975757 0.79 ESR1 (0.43) CA12CA1CA2CA4CA9
SCHEMBL15975758 0.79 ESR1 (0.43) CA12CA1CA2CA4CA9
SCHEMBL126319 0.79 ESR1 (0.43) CA12CA1CA2CA4CA9
SCHEMBL12879524 0.79 ESR1 (0.43) CA12CA1CA2CA4CA9
SCHEMBL103830 0.79 ESR1 (0.43) CA12CA1CA2CA4CA9
SCHEMBL480205 0.78 APP (0.60) CYP2C9CA12CA1CA2CA9
SCHEMBL12124384 0.78 APP (0.60) CYP2C9CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10300697-A None JP disclosed
US-9346768-B2 Molecular glasses with functionalizable groups HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENSE (CA) 2016-05-24 US disclosed
US-9346768-B2 Molecular glasses with functionalizable groups HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENSE (CA) 2016-05-24 US disclosed
US-9328076-B2 Molecular glasses with functionalizable groups HER MAJESTY IN THE RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF DEFENSE (CA) 2016-05-03 US disclosed
US-9328076-B2 Molecular glasses with functionalizable groups HER MAJESTY IN THE RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF DEFENSE (CA) 2016-05-03 US disclosed
US-20150232433-A1 Molecular Glasses With Functionalizable Groups HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) 2015-08-20 US disclosed
US-20150232433-A1 Molecular Glasses With Functionalizable Groups HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) 2015-08-20 US disclosed
US-20140005370-A1 MOLECULAR GLASSES WITH FUNCTIONALIZABLE GROUPS HER MAJESTY THE QUEEN IN RIGHT OF CANADA AS REPRESENTED BY THE MINISTER OF NATIONAL DEFENCE (CA) 2014-01-02 US disclosed
JP-H10300697-A GAS SENSOR SHIMADZU CORP 1998-11-13 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005370-A1 MOLECULAR GLASSES WITH FUNCTIONALIZABLE GROUPS GNG2, GDI1, F12 HDAC8 4268/4885PTPN1 1125/4885CYP2C9 4718/4885
US-20150232433-A1 Molecular Glasses With Functionalizable Groups GDI1, GNG2, F12 HDAC8 4299/4885PTPN1 1317/4885CYP2C9 4712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.